Repository logo
 
Publication

Lipid nanocarriers for anti-HIV therapeutics: a focus on physicochemical properties and biotechnological advances

2021-08-19Journal article Open access
Simple item page
dc.contributor.authorFaria, Maria João
dc.contributor.authorLopes, Carla Martins
dc.contributor.authordas Neves, José
dc.contributor.authorLúcio, Marlene
dc.date.accessioned2021-09-15T09:08:54Z
dc.date.available2021-09-15T09:08:54Z
dc.date.issued2021-08-19
dc.description.abstractSince HIV was first identified, and in a relatively short period of time, AIDS has become one of the most devastating infectious diseases of the 21st century. Classical antiretroviral therapies were a major step forward in disease treatment options, significantly improving the survival rates of HIV-infected individuals. Even though these therapies have greatly improved HIV clinical outcomes, antiretrovirals (ARV) feature biopharmaceutic and pharmacokinetic problems such as poor aqueous solubility, short half-life, and poor penetration into HIV reservoir sites, which contribute to the suboptimal efficacy of these regimens. To overcome some of these issues, novel nanotechnology-based strategies for ARV delivery towards HIV viral reservoirs have been proposed. The current review is focused on the benefits of using lipid-based nanocarriers for tuning the physicochemical properties of ARV to overcome biological barriers upon administration. Furthermore, a correlation between these properties and the potential therapeutic outcomes has been established. Biotechnological advancements using lipid nanocarriers for RNA interference (RNAi) delivery for the treatment of HIV infections were also discussed.pt_PT
dc.description.versioninfo:eu-repo/semantics/publishedVersionpt_PT
dc.identifier.citationFaria, M.J.; Lopes, C.M.; das Neves, J.; Lúcio, M. Lipid Nanocarriers for Anti-HIV Therapeutics: A Focus on Physicochemical Properties and Biotechnological Advances. Pharmaceutics 2021, 13, 1294. https://doi.org/10.3390/ pharmaceutics13081294pt_PT
dc.identifier.doi10.3390/pharmaceutics13081294pt_PT
dc.identifier.issn1999-4923
dc.identifier.urihttp://hdl.handle.net/10284/10209
dc.language.isoengpt_PT
dc.peerreviewedyespt_PT
dc.publisherMDPIpt_PT
dc.relationFCT/MCTES—Foundation for Science and Technology I.P. from the Minister of Science, Technology, and Higher Education (PIDDAC) and European Regional Development Fund (ERDF) by the COMPETE—Programa Operacional Factores de Competitividade (POFC) through the project CONCERT [POCI-01-0145-FEDER-032651 and PTDC/NAN-MAT/326512017] and the Strategic Funding UID/FIS/04650/2019pt_PT
dc.relation"Contrato-Programa” UIDB/04469/2020 (CF-UM-UP and CBMA)pt_PT
dc.relation.publisherversionhttps://www.mdpi.com/1999-4923/13/8/1294pt_PT
dc.subjectARV deliverypt_PT
dc.subjectBiotechnology in ARVpt_PT
dc.subjectBiological barrierspt_PT
dc.subjectLipid emulsionspt_PT
dc.subjectLipid nanoparticlespt_PT
dc.subjectLiposomespt_PT
dc.subjectRNAi and ARV codeliverypt_PT
dc.titleLipid nanocarriers for anti-HIV therapeutics: a focus on physicochemical properties and biotechnological advancespt_PT
dc.typejournal article
dspace.entity.typePublication
oaire.citation.issue8pt_PT
oaire.citation.titlePharmaceuticspt_PT
oaire.citation.volume13pt_PT
person.familyNameLopes
person.givenNameCarla
person.identifier.ciencia-id901D-160C-633E
person.identifier.orcid0000-0001-5080-032X
person.identifier.ridM-4689-2016
person.identifier.scopus-author-id26649517700
rcaap.rightsopenAccesspt_PT
rcaap.typearticlept_PT
relation.isAuthorOfPublicationd2a48cfe-9258-4916-99be-bbcb710f6605
relation.isAuthorOfPublication.latestForDiscoveryd2a48cfe-9258-4916-99be-bbcb710f6605

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Pharmaceutics-13-01294.pdf
Size:
6.98 MB
Format:
Adobe Portable Document Format
Download

Collections

FCS - Artigos em Revistas Científicas Internacionais com Arbitragem Científica